Accession Number: | 0001209191-21-026633 |
Date: | 2021-04-12 |
Issuer: | DECIPHERA PHARMACEUTICALS, INC. (DCPH) |
Original Submission Date: |
BRISTOL JAMES ARTHUR
C/O DECIPHERA PHARMACEUTICALS, INC.
200 SMITH STREET
WALTHAM, MA 02451
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-04-12 | M | 14,700 | a | $3.95 | 14,700 | direct | ||
COMMON STOCK | 2021-04-12 | S | 9,483 | d | $43.70 | 5,217 | direct | ||
COMMON STOCK | 2021-04-12 | S | 5,217 | d | $44.09 | 0 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 3.95 | 2021-04-12 | deemed execution date | M | 14,700 (d) | 2026-09-26 | common stock 14,700 | $3.95 | 29,150 | direct |
ID | footnote |
---|---|
f1 | the sales reported in this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on november 19, 2020. |
f2 | the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $43.01 to $44.00, inclusive. the reporting person undertakes to provide to deciphera pharmaceuticals, inc., any security holder of deciphera pharmaceuticals, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
f3 | the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $44.01 to $44.36, inclusive. the reporting person undertakes to provide to deciphera pharmaceuticals, inc., any security holder of deciphera pharmaceuticals, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
f4 | this stock option award was issued pursuant to deciphera pharmaceuticals, llc's 2015 equity incentive plan. the option was 100% exercisable as of july 31, 2020. |